Teva stock jumped early Wednesday after the generic drugs behemoth reported adjusted earnings of 48 cents per share on $3.82 billion in first-quarter sales.
On average, analysts surveyed by FactSet expected Teva Pharmaceutical (TEVA) to earn 52 cents per share and report $3.74 billion in sales.
In the year-earlier period, Teva earned 40 cents a share on $3.66 billion in sales.
For the year, Teva reaffirmed its outlook for adjusted profit of $2.20 to $2.50 per share and $15.7 billion to $16.3 billion in sales. The Street projected $2.39 earnings per share and $15.8 billion in sales.
https://www.investors.com/news/technology/teva-stock-teva-pharmaceutical-earnings-q1-2024/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.